Our findings not only shed light on the underlying mechanisms of eIF4F-mediated resistance to BRAF and MEK inhibitors in melanoma, but they also indicate the possibility of pharmacologically disrupting critical control mechanisms adjusting active ERK levels and allowing melanoma cells to thrive despite potent activating mutations in the ERK pathway. Here, EIF4G1 is linked to melanoma.